Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2013 - 2026)

Regeneron Pharmaceuticals' Other Non Operating Income history runs 14 years deep, the most recent figure standing at $245.3 million for Q2 2026.

• In Q2 2026, Other Non Operating Income fell 44.6% year-over-year to $245.3 million; the TTM figure through Jun 2026 stood at $1.4 billion (up 28.75% YoY), while the FY2025 annual figure was $1.7 billion, up 100.92% from the prior year.
• Other Non Operating Income for Q2 2026 stood at $245.3 million, up from $201.2 million in the prior quarter.
• The five-year high for Other Non Operating Income was $755.8 million in Q3 2025, with the low at -$183.8 million in Q1 2022.
• The 5-year median for Other Non Operating Income is $194.1 million (2022), against an average of $188.4 million.
• Peak annual rise in Other Non Operating Income reached 1937.8% in 2022, while the deepest fall reached 218.66% in 2022.
• Regeneron Pharmaceuticals' Other Non Operating Income stood at $195.3 million in 2022, then fell by 1.18% to $193.0 million in 2023, then slumped by 111.19% to -$21.6 million in 2024, then surged by 914.81% to $176.0 million in 2025, then soared by 39.38% to $245.3 million in 2026.
• Business Quant data shows REGN's Other Non Operating Income at $245.3 million in Q2 2026, $201.2 million in Q1 2026, and $176.0 million in Q4 2025.